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Many clinical abnormalities in atopic eczema have 
been attributed to an imbalance in autonomic nervous 
system control, specifically a partial blockade of beta-
adrenergic responsiveness. The lysosomal enzyme beta-
glucuronidase is released from granulocytes during in 
vitro incubation with complement-activated zymosan 
particles. Isoproterenol will inhibit ·the release of this 
lysosomal enzyme from the granulocyte and the isopro-
terenol effect is associated with increased granulocyte 
cyclic AMP formation. In atopic eczema and asthma, this 
granulocyte r esponse to isoproterenol is impaired. His-
tamine also inhibits in vitro zymosan induced release of 
beta-glucuronidase and this is an H2 histamine effect. In 
asthma, this H2 histamine response is diminished. In the 
following study, we found a similar impairment in his-
tamine inhibition of beta-glucuronidase release and for-
mation of granulocyte cAMP in atopic eczema. This de-
fect was found only in granulocytes from patients with 
active eczema. Thus in active atopic eczema, defects in 
the pharmacological response of the granulocyte are not 
limited to beta-adrenergic agonists but include H2 his-
tamine activity. 
The pathogenesis of atopic eczema remains to be established. 
Considerable attention has focused on the existence of an 
imbala nce in autonomic nervous system responsiveness a nd its 
re lationship to the change in atopic eczema [1-6). Szentivanyi 
[7] proposed these abnormalities in atopic eczema may be due 
to a partial blockade of the be ta-adrenergic receptor s ites in the 
involved tissues. Support for this hypothesis can be found in 
both in vivo and in vitro observations [8,9). To bette r define 
a nd ch a racterize these changes, we have examined beta-adre-
nergic activity in isolated granulocytes (PMNs) from patients 
with atopic diseases. Release of inflammatory lysosomal en-
zym es from granulocytes follows phagocytosis [10,11], which 
can be co nveniently investigated by incubating PMNs in the 
presence of complem ent-activated particles of zymosan. Isopro-
terenol a nd pros taglandin EI inhibit release of lysosomal en-
zym e a nd this is associated with an increase in intracellulaj' 
cyclic adenosine monophosphate (cAMP) [12,13). In atopic 
eczema and also asthma, we have found the granulocyte r e-
sl?~nse to isopro terenol impaired while prostaglandin E , inhi-
bitIOn of lysosomal enzyme release and formation of cAMP is 
normal [14,15). 
The presence of IgE m ediated sensitivity is common in atopic 
eczema. Identifying the relationship ofIgE hypersensitivity and 
its mediator histamine to the development of atopic eczema is 
speculative. Histamine, like isoproterenol a nd prostaglandin EI, 
inhibits lysosomal enzyme release from granulocytes when in-
cubated with serum-activated zymosan [13]. We have found 
t his histamin e effect mediated by the H2 receptor and to 
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paralle l an increase in PMN intracellular cAMP [16]. In asthma, 
the granulocyte H2 histamine receptor is impaired [17]. The 
following r eports the existence of a similar defect in granulocyte 
H 2 histamine response in atopic eczema but only when the skin 
disease is active. 
MATERIALS AND METHODS 
Patient SeLection 
Adul t volun teers from the University of Wisconsin Allergy Clinic 
and the Dermatology Clinic at the University of Wisconsin Health 
Service were selected for study. Nine patients had chronic, active 
eczema and ranged in age from 20 to 62 yr old (average age was 30 yr). 
The subj ects with active eczema had skin lesions involving the popliteal 
and antecubita l fossae as well as the trunk and extremities. They had 
marked pruritus, and the lesions were lichenified, erythematous, and 
scaly. None were receiving systemic corticosteroids, antihistamines or 
other medications, except topical corticosteroid preparations. In addi-
tion, these individuals did not have asthma or a history of asthma. Six 
of the nine patients were female. Five additional patients had a history 
of eczema which, at the time of study, had been inactive for at least 1 
mo. These subjects had normal appearing skin at the time of study. 
However, a ll patients had a documented history of ac tive atopic eczema 
as described above which had been present within the past year . Two 
of this group were males and the 5 patients ranged in age from 19 to 25 
with a mean age of 22 yl". Six normal subjects served as controls and 
ranged in age from 22 to 57 with an average age of 32. Sex distribution 
of the controls was equal. None of the control subjects had a history of 
eczema, a llergic disease, or was receiving medicat ion. 
MateriaLs 
The H2 antih istamine metiamide was the kind gift of Smith, Kline 
and French Laboratories (Philadelphia, Pennsylvania) . Histamine di-
phosphate was purchased from ICN Nutritional Biochemicals Division, 
In te rnational Chemical and Nuclea r Corporation (Cleveland, Ohio). 
Zymosan, theophyll ine, pyrilamine maleate, and phenolphthalein glu-
curonidate were purchased from Sigma Chemical Company (St. Louis, 
Missouri) . Cytochalasin B was obta ined from Aldrich Chemical Com-
pany (Mi lwaukee, Wisconsin) and dissolved in 0.1 % dimethyl sulfoxid e 
(DMSO). This concentration of DMSO did not alter enzyme release. 
Cell Prepara/.ion 
Anticoagu lated blood (2.7% ethylenediaminetetracetic ac id) was sep-
arated by Ficoll-Hypaque density gradient centrifugation as described 
by Boyum [18], and the isolated granulocytes were suspended in Hanks' 
balanced salt solution (HBSS) in a final concentration of 3 x IOH PMNs 
per ml (98% PMNs). 
Lys08onw.1 Enzyme Det.erminat.ions 
Replicate 0.5 ml samples of PMN suspension (3 x lOH PMN/ml) 
were placed in 10 X 75 mm plastic test tubes and preincubated wi th 5 
meg of cytochalasin B per ml for 5 minutes at 37"C. The use of 
cytochalasin B a llows for selective lysosomal enzyme release indepen-
dent of part icle ingestion [19]. In studies involving drugs, the cells were 
preincubated with 50 /lM theophylline for 15 min prior to the addition 
of histamine (x 15 min). The theophylline concentra tion did not 
significantly affect either lysosomal enzyme release or the concentration 
of cAMP. Antihistamines, metiamide or pyrilamine, were added 5 min 
prior to histamine. 
The methods used in zymosan-induced lysosomal enzyme release 
were those previously described [17]. Briefly, zymosan was boiled in 
saline for 10 min, washed twice, and resuspended in HBSS (10 mg per 
ml). The isolated granulocytes, 3 X 10'; PMN/ml in HBSS, were 
preincubated with CB, theophylline, and histamine (with or without 
antagonists!. before 50 ,11 each of autologous serum and zymosan were 
added. Following a 30 min incubation at 37°C in a shaking water bath 
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(120 cycles per minute), the reaction was stopped by centrifugation 
(750 g x 10 min at 4°C). The cell-free supernatant was removed for 
enzyme determination. Total PMN enzyme activi ty was obtained after 
ce ll lysis with 0.2% Triton X-l00 (Rohm and Hass Company, Philadel-
phia, Pennsylvania). 
The lysosomal enzyme, beta-glucuronidase, was determined a(ter 18 
hr of incubation at 37°C with phenolphthale in glucuronidate as sub-
strate [20]. 
The percent inhibi t ion of lysosomal enzyme release was calculated 
by comparing the zymosan-stimulated enzyme release of histamine 
treated cells to that of untreated cells . Cell viab ility was mainta ined as 
determined by a greater than 95% exclusion of trypan blue dye. 
The cAMP Determination 
PMNs (3 x 10" ce lls per ml) were preincubated with theophylline 
(50 11M x 15 min at 37°C) and then histamine (l0- " M x 5 min). T he 
cells were co Ll ected by centrifugation at 750 g for 10 min at 4°C, and 
cAMP was extracted from the cell pellet by ethanol. After recentrifug-
ing, t he ethanol fractions were removed and dried under N~ . The cAMP 
concentration was determined by a saturation assay method [21] and 
the increase in granulocyte cAMP is expressed as the percent change 
over baseline levels 
(
pmols/ lO" PMNs stimulated ) (' x 100% . pmols/ 1O' PMNs baseline 
Statist ics 
Statistical significance (p) was calculated using Student's t-test. 
RESULTS 
Granulocyte Concentration of the Lysosomal Enzyme Beta-
Glucuronidase and its Release During Incubation with 
Serum Activated Zymosan (Table I) 
In the PMNs from controls, active eczema, and inactive 
eczema, the concentration of beta-glucuronidase was similar. 
Following treatment with CB and incubation with zymosan and 
TABLE I. Comparison of beta·glucuronidase concentration in 
granulocytes and release following incubation with autologous 
serum and zymosan (m.ectn ± SE) 
Normal (N = 6) 
Active eczema (N = 9) 
Inactive eczema (N = 5) 
T otal enzyme" 
68.8 ± 5.6 
69.0 ± 4.7 
71.0 ± 4.6 
" mcg phenolphtha lein/ lO" PMN/18 hr. 
Zymosan sti mulated 
release" 
21.7 (31.6%)" ± 0.9 
22.7 (32.9%) ± 1.4 
21.9 (30.8%) ± 2.2 
/, Percent of total enzyme release fo llowing 30 min incubation with 
autologous serum and zymosan. 
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autologous serum, the release of beta-glucuronidase was iden-
tical in all 3 study groups. 
Histamine Inhibition of Beta-Glucuronidase Release (Table 
II) 
Histamine inhibits zymosan induced release ofbeta-glucuron-
idase in a dose-dependent fashion. At 100 JlM histamine, the 
inhibition of lysosomal enzyme release was similar in PMNs 
from normal and inactive eczema subjects (37.2 ± 1.6% and 34.7 
± 2.9%, respectively) and this concentration of histamine pro-
duced maximal inhibition. In active eczema, the PMN response 
to 100 /lM histamine (25.8 ± 1.8%) was significantly less than 
noted in the other 2 groups. This granulocyte response to 
histamine in active eczema was also significantly impaired to 
an other drug concentrations (1O- r. to 10- 7 M) tested. Higher 
concentrations of histamine (10- :1 and 1O-~ M) were not tested 
with cens from active eczema and maximal inhibition of enzyme 
release may have occurred with these doses. 
The Effect of Metiamide on Histamine Inhibition of 
Lysosomal Enzyme Release (Table III) 
The PMN response to histamine was antagonized by the H2 
antihistamine metiamide. Equimolar concentrations ofmetiam-
ide and histamine resulted in the neutralization of histamine 
activity. This antagonism occurred in PMNs from all three 
study groups. In active eczema, there was a slightly enhanced 
(8.2 ± 0.8%) release of beta-glucuronidase by histamine 00-" 
M) when incubated with 10- 4 M metiamide. T his effect did not 
occur with granulocytes from control or inactive eczema sub-
jects. 
The HI antagonist, pyrilamine, did not alter the histamine 
inhibition of beta-glucuronidase release when tested in concen-
trations from 10- 8 to 10-.1 M (data not shown). 
Cyclic AMP Response to Histamine in the Granulocyte 
(Tab le IV) 
In 3 patients from each study group, histamine stimulation 
of cAMP formation was compared to its ability to inhibit 
lysosomal enzyme release. The paired observations were done 
on the same patient. The baseline levels of cyclic AMP were 
similar in all 3 groups. In active eczema, granulocyte cAMP 
formation during incubation with a single dose of histamine 
(10- " M) was significantly (p < 0.05) reduced when compared to 
cells from normal subjects and inactive eczema. The diminished 
cyclic nucleotide formation paralleled the impairment in his-
tamine inhibi tion of lysosomal enzyme release. 
TABLE II . Comparison of the percent histamine inhibition of the lysosomal enzyme, beta-glucuronidase, release. Values are expressed as the 
mean percent ± SE. 
Normals (N = 6) 
Active eczema (N = 9) 
Inactive eczema (N = 5) 
" = p < 0.02 
"= P < 0.01 
,. = P < 0.001 I compared to active eczema 
18.4 ± 0.9' 
8.5 ± 1.5 
17.7 ± 3.0" 
25.4 ± 1.8' 
14.4 ± 1.6 
23.1 ± 3.2" 
Histamine (M) 
34 .3 ± 1.0' 
20.4± 1.9 
30.7 ± 3.3" 
37.2 ± 1.6" 
25.8 ± 1.8 
34.7 ± 2.9" 
TABLE III. The effect of the H2 antihistamine metiamide on the inhibition of beta-glucuronidase release by 10-' M histamin e. The value is 
the mea.n percent inhibition ± SE. 
Normal (N = 6) 
Active eczema (N = 5) 
Inactive eczema (N = 5) 
" Enhanced release. 
37.2 ± 1.6 
24.2 ± 2.0 
34.7 ± 2.9 
32.9 ± 1.9 
20. 1 ± 1.9 
31.2 ± 4.0 
Hist.am ine 10-" M 
plus l11e tiamide (M) 
30.4 ± 1.8 
17.4±1.7 
25.9 ± 4.5 
22.6 ± 2.5 
9.6 ± 1.4 
19.7 ± 4.2 
+0.8 ± 2.0" 
+8.2 ± 0.8" 
1.4 ± 3.6 
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TABLE IV. Comparison of baseline concentrations of PMN cAMP, cAMP formation by histamine, and histamine inhibition of beta-
glucuronidase release: values are the mean ± SE 
Normal (N = 3) 
Active eczema (N = 3) 
Inactive eczema (N - 3) 
" = p < .05 compared to active eczema. 
DISCUSSION 
3.3 ± 0.5 
2.7 ± 0.4 
2.5 + 0.3 
In active atopic eczema, the isolated granulocyte has an 
impaired H 2 histamine response in both the formation of PMN 
cyclic AMP and inhibit ion of zymosan-induced release of the 
lysosomal enzyme beta-glucuronidase. The finding of an im-
paired granulocyte H2 histamine response in active atopic 
eczema parallels a similar neutrophil defect in asthma [17]. The 
abnormal histamine response in both diseases is not absolute, 
but represents only a diminished response. From our present 
data, it is not possible to determine if the diminish ed granulo-
cy te response in active atopic eczema represents a decrease in 
total number of histamine receptors or an a ltered affinity of the 
receptor . 
The isolated granulocyte in atopic eczema and asthma has 
also been characterized as having impaired beta-adrenergic 
responsiveness to isoproterenol. The existence of beta-adrener-
gic blockade' does not contribute to the impaired H2 histamine 
response. Pretreatment of PMNs with propranolol does not 
alter histamine inhibition of lysosomal enzyme release [17], nor 
does the defect in PMN histamine response appear to be the 
result of a generalized impairment to all agonists. In both atopic 
eczema and asthma, prostaglandin E, will inhibi t enzyme 
re lease and stimulate cyclic AMP formation in a normal fashion 
[14,15]. 
H istamine's role in the pathogenesis of eczema is not clear. 
Confirming the proposal by Ash and Schild [22] that at least 2 
types of receptors are involved in the histamine response has 
stimulated and renewed interest in this mediator a nd its effect 
on both inflammation and immunity. HI histamine responses 
include vasodilation and smooth muscle contraction specifically 
blocked by the classical a ntihistamines m epyramine, diphen-
hyd]'amine, and chlorpheniramine. The HI media ted reactions 
are generally involved in ini tiating an inflammatory response. 
Histamine stimulation will also stimulate gastric acid secretion, 
rat uterine muscle relaxation, and guinea pig atrium contraction 
which are not blocked by the above ant ihistamines. Conftrming 
the presence of H 2 histamine receptors was possible with the 
discovery of a new class of histamine antagonists, burimamide, 
metiamide, and cimetidine, which specifically blocked the sec-
ond group of responses to histamine but not the ftrst. 
H2 histamine receptors have been identified on leukocytes 
and serve to modulate their function. This is illustrative in a 
number of examples. Histamine is released from IgE sensitized 
mast cells and basophilic leukocytes upon specific an t igen chal-
lenge. In addition to mediating a naphylaxis, histamine inhibi ts 
the in uitro a ntigen-induced release of histamine from leuko-
cytes of allergic individuals [23]. This is an H2 receptor response 
[24]. Murine lymphocyte cytolysis [25] and release of lympho-
cyte migration inhibi tion factor [26] are also inhibited by his-
tamine stimulation of the H2 receptor. 
Hill and Quie [27] reported defective neu trophil chemotaxis 
in 3 childj'en with active eczema and recurrent bacterial infec-
tions. They found histamine inhibited neutrophil chemotaxis 
and from these observations the authors speculated that this 
granulocyte defect may arise as the result of increased hista-
mine release in atopic eczema patients. The existence of in-
creased histamine release in eczema is speculative but offers a 
potential explanation for our findings. Receptor desensit ization 
to catecholamines is well recognized. Catecholamines are ca-
% increase cAMP 
189 ± 22.0" 
134 ± 6.0 
173 ± 13.0" 
His tamine (lO- r·M ) 
% Inhi bition of lysosomal enzyme 
release 
33.3 ± l.8" 
21.4 ± 3.5 
26.2 ± 2.3 
pa ble of stimulating adenylate cyclase in many cell systems. If 
the cells are exposed to catecholamines, t he subsequent stimu-
lation of adenyla te cyclase with the same adrenergic agonist is 
impaired [28]. P laut [29] has shown the same phenomenon to 
occur with histamine. Incubation of lymphocytes with hista-
mine will impau' this agonist from inhibiting lymphocyte cytol-
ysis upon subsequent exposure. It is t herefore conceivable t hat 
increased concentrations of histamine in active eczema would 
serve to subsequently impair histamine inhibit ion of lysosomal 
enzym e release from granulocytes. S imilarly, if this H2 defec t 
were generalized and found on mast cells and basophilic leu-
kocytes, a major feedback inhibition of histamine is lost. This 
could lead to a n enhanced r elease of histamine. 
These findings do not identify a role for histamine in t h e 
.pathogenesis of atopic eczema, nor the .mec?anism of. the irn-
pau'ed PMN H2 histamine response a nd Its cllmcal slgmficance. 
This impairment was confined to pa tients with active atopic . 
eczem a . However, these patients were not studied at a time 
when their disease was quiescen t. Therefore, it is not ftrmly 
established that this impau'ment will recover as the disease 
becomes inactive . Our observations do indicate a similarity in 
the impaired pharmacological response to histamine in asthma 
and atopic eczema in addition to the defect previously found 
with f3-adren ergic agonists. Our study also indica.tes the poten-
tial usefulness of the isolated granulocyte as an tn ultra model 
to study agonist response in these diseases. 
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